IMO-8400 regulatory update

FDA granted Orphan Drug designation to IMO-8400 from Idera to treat diffuse large B cell lymphoma (DLBCL). The toll-like receptor 7 (TLR7), TLR8 and TLR9 antagonist is in Phase I/II testing to trea...